179 related articles for article (PubMed ID: 31993743)
1. Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF
J Cancer Res Clin Oncol; 2020 Mar; 146(3):695-704. PubMed ID: 31993743
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Sit AS; Price FV; Kelley JL; Comerci JT; Kunschner AJ; Kanbour-Shakir A; Edwards RP
Gynecol Oncol; 2000 Nov; 79(2):196-200. PubMed ID: 11063643
[TBL] [Abstract][Full Text] [Related]
3. Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Duman BB; Kara IO; Günaldi M; Ercolak V
Arch Gynecol Obstet; 2011 Jun; 283(6):1363-8. PubMed ID: 21298439
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary.
Duska LR; Garrett A; Eltabbakh GH; Oliva E; Penson R; Fuller AF
Gynecol Oncol; 2002 Jun; 85(3):459-63. PubMed ID: 12051874
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy.
Inthasorn P; Beale P; Dalrymple C; Carter J
Aust N Z J Obstet Gynaecol; 2003 Feb; 43(1):61-4. PubMed ID: 12755351
[TBL] [Abstract][Full Text] [Related]
6. Malignant mixed müllerian tumor of primary mesenteric origin associated with a synchronous ovarian cancer: case report and literature review.
Ma CJ; Yang SF; Huang CC; Chai CY; Cheng KI; Tsai EM; Wang JY
Eur J Gynaecol Oncol; 2008; 29(3):289-93. PubMed ID: 18592799
[TBL] [Abstract][Full Text] [Related]
7. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
8. Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy.
Mok JE; Kim YM; Jung MH; Kim KR; Kim DY; Kim JH; Kim YT; Nam JH
Int J Gynecol Cancer; 2006; 16(1):101-5. PubMed ID: 16445618
[TBL] [Abstract][Full Text] [Related]
9. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
McCourt C; Dessie S; Bradley AM; Schwartz J; Brard L; Dizon DS
Int J Gynecol Cancer; 2009 Apr; 19(3):343-7. PubMed ID: 19407557
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
Kudlowitz D; Velastegui A; Musa F; Muggia F
Cancer Chemother Pharmacol; 2018 May; 81(5):847-851. PubMed ID: 29516152
[TBL] [Abstract][Full Text] [Related]
12. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma.
Tong SY; Lee JM; Choi YJ; Lee JK; Kim JW; Cho CH; Kim SM; Park SY; Park CY; Kim KT
Aust N Z J Obstet Gynaecol; 2012 Feb; 52(1):44-8. PubMed ID: 22188343
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival of stage IV malignant mixed Müllerian tumor of the ovary after carboplatin, mesna, ifosfamide, and cis-platin chemotherapy: case report.
Di Vagno G; Cormio G; Loverro G; Melilli GA; Di Gesù G; Selvaggi L
J Chemother; 1998 Oct; 10(5):418-21. PubMed ID: 9822362
[TBL] [Abstract][Full Text] [Related]
14. Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy.
Muntz HG; Jones MA; Goff BA; Fuller AF; Nikrui N; Rice LW; Tarraza HM
Cancer; 1995 Oct; 76(7):1209-13. PubMed ID: 8630899
[TBL] [Abstract][Full Text] [Related]
15. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
16. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
18. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin.
Tirmazy SH; Barthakur U; El-Modir A; Anwar S; Fernando I
Anticancer Res; 2014 Jul; 34(7):3793-8. PubMed ID: 24982404
[TBL] [Abstract][Full Text] [Related]
20. Malignant mixed müllerian tumors of the ovary.
Wei CF; Hwang SH; Ho CM; Shih BY; Chien TY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr; 63(4):344-8. PubMed ID: 10820916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
